Synthesis and Calcium Channel-Modulating Effects of Alkyl (or Cycloalkyl) 1,4-Dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate Racemates and Enantiomers
- 17 January 1998
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (4) , 509-514
- https://doi.org/10.1021/jm9704006
Abstract
A group of racemic alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-, 3-, or 4-pyridyl)-5-pyridinecarboxylate isomers (6 − 14) were prepared using a modified Hantzsch reaction that involved the condensation of nitroacetone with an alkyl (or cycloalkyl) 3-aminocrotonate and 2-, 3-, or 4-pyridinecarboxaldehyde. Determination of their in vitro calcium channel-modulating activities using guinea pig ileum longitudinal smooth muscle (GPILSM) and guinea pig left atrium (GPLA) assays showed that the 2-pyridyl isomers acted as dual cardioselective calcium channel agonists (GPLA)/smooth muscle selective calcium channel antagonists (GPILSM). In contrast, the 3-pyridyl and 4-pyridyl isomers acted as calcium channel agonists on both GPLA and GPILSM. In the C-4 2-pyridyl group of compounds, the size of the C-5 alkyl (or cycloalkyl) ester substituent was a determinant of GPILSM antagonist activity where the relative activity profile was cyclopentyl and cyclohexyl > t-Bu, i-Bu, and Et > MeOCH2CH2 > Me. The point of attachment of the C-4 pyridyl substituent was a determinant of GPLA agonist activity where the potency order was generally 4- and 3-pyridyl > 2-pyridyl. (+)-Cyclohexyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-pyridyl)-5-pyridinecarboxylate [(+)-14a] was a less potent calcium antagonist (IC50 = 5.27 × 10-6 M) than the (−)-enantiomer (IC50 = 7.48 × 10-8 M) on GPILSM. In the GPLA assay, (+)-14a exhibited a much more potent agonist effect (EC50 = 8.45 × 10-6 M) relative to the marginal agonist effect produced by (−)-14a. The C-4 2-pyridyl compounds (enantiomers) constitute a novel type of 1,4-dihydropyridine calcium channel modulator that could provide a new drug design concept directed toward the treatment of congestive heart failure, and for use as probes to study the structure−function relationships of calcium channels.Keywords
This publication has 9 references indexed in Scilit:
- Ion channels as pharmacologic receptors: The chirality of drug interactionsChirality, 1996
- Calcium channels: Structure, function, and classificationDrug Development Research, 1994
- Molecular level model for the agonist/antagonist selectivity of the 1,4-dihydropyridine calcium channel receptorJournal of Computer-Aided Molecular Design, 1991
- Dimeric 1,4-dihydropyridines as calcium channel antagonistsJournal of Medicinal Chemistry, 1988
- Ca2+ agonists: new, sensitive probes for Ca2+ channelsTrends in Pharmacological Sciences, 1988
- Synthesis and calcium channel antagonist activity of dialkyl 4-(dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylatesJournal of Medicinal Chemistry, 1987
- Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylatesJournal of Medicinal Chemistry, 1986
- Positive inotropic actions of the calcium channel stimulator, Bay k 8644, in awake, unsedated dogsBasic Research in Cardiology, 1985
- Novel dihydropyridines with positive inotropic action through activation of Ca2+ channelsNature, 1983